SCHEMBL26089565

SCHEMBL26089565

Cc1ccc(F)cc1S(=O)(=O)Nc1cc(Cl)cc(-c2nc(C(C)(C)C)sc2-c2ccnc(N)n2)c1F

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 20/20 0.88
NR1I2 O75469 7/20 0.88
PLK4 O00444 1/20 0.59
EPHB6 O15197 1/20 0.59
RIPK2 O43353 1/20 0.59
JAK2 O60674 1/20 0.59
ULK1 O75385 1/20 0.59
ERN1 O75460 1/20 0.59
PRKD3 O94806 1/20 0.59
ABL1 P00519 1/20 0.59
KRAS P01116 1/20 0.59
RAF1 P04049 1/20 0.59
LCK P06239 1/20 0.59
FYN P06241 1/20 0.59
CDK1 P06493 1/20 0.59
YES1 P07947 1/20 0.59
LYN P07948 1/20 0.59
MET P08581 1/20 0.59
HCK P08631 1/20 0.59
FGR P09769 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30378585 1.00 BRAF (0.88) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL23458311 0.94 BRAF (1.00) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL30163071 0.94 BRAF (1.00) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2191640 0.89 BRAF (0.75) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL29721355 0.86 BRAF (0.86) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL23458264 0.86 BRAF (0.86) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL2190522 0.83 BRAF (0.81) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL30378358 0.83 BRAF (0.73) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL26087982 0.83 BRAF (0.73) BRAFNR1I2PLK4EPHB6RIPK2
SCHEMBL30378645 0.83 BRAF (0.62) BRAFNR1I2RIPK2CDK4IRAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230151-A1 COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2025-07-17 US claimed
WO-2023070076-A1 COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-04-27 WO claimed
US-20250230151-A1 COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2025-07-17 US disclosed
WO-2023070076-A1 COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230151-A1 COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION BRAF, ABCB1, NRAS BRAF 1/4885NR1I2 1608/4885PLK4 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.